))
Episode 22. Management of Low-Risk MDS
Manage episode 363911680 series 3369804
Content provided by Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this episode, we take a deep dive into low-risk MDS management. We have the privilege of being joined by the esteemed Dr. Mikkael Sekeres. We also explore his invaluable insights gained from his time at FDA ODAC and his latest literary endeavor, "Drugs and the FDA".
Here are the key studies discussed:
1. ASH choosing wisely:
https://www.hematology.org/education/clinicians/guidelines-and-quality-care/choosing-wisely
2. International Consensus Classification (ICC):
https://pubmed.ncbi.nlm.nih.gov/35767897/
3. WHO classification 2022:
https://pubmed.ncbi.nlm.nih.gov/35732829/
4. IPSS-M:
https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200008
5. Romiplostim in MDS:
https://pubmed.ncbi.nlm.nih.gov/29396092/
6. Low-dose decitabine vs. low-dose azacItidine in lower-risk MDS:
https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200034
7. Luspatercept in MDS:
https://www.nejm.org/doi/full/10.1056/nejmoa1908892
8. Lenalidomide in MDS:
https://ascopubs.org/doi/10.1200/JCO.2015.66.0118
https://pubmed.ncbi.nlm.nih.gov/21753188/
9.Iron chelation therapy in MDS:
https://pubmed.ncbi.nlm.nih.gov/32203980/
48 episodes
Share
